November 1, 2018 (Vol. 38, No. 19)
The shift of the biopharmaceutical industry from traditional stainless-steel bioprocessing equipment to disposables is mainly influenced by proven economic and operational benefits of single-use technology (SUT) bioprocess engineering, according to a report from Grand View Research. Key advantages associated with SUT include reduced risk of cross-contamination, lower capital expenditure, and flexibility in accommodating changing consumer needs.
In the current scenario, biopharmaceutical producers are embracing the trend of disposables. This is due to the emergence of SUTs as a widely acceptable choice among contract manufacturing organizations (CMOs). This technology is expected to witness surging profit in the coming years with a growing CMO base for biopharmaceutical production, notes the Grand View study.
Rising demand for biologics and biosimilars has raised the pressure to reduce overall production costs while maintaining product quality. This has helped disposable solutions gain ground for bioproduction. This is mainly because SUTs are known to significantly reduce operation and manufacturing costs.
“At present, the main goal of biomanufacturers is rapid launch and commercialization of biopharmaceuticals. This has led to growing interest in disposables for bioproduction within the bioprocessing industry,” states Grand View Research.
To provide GEN readers with an update on the trends for single-use technology, this special GEN supplement features the following articles:
We hope this supplement will help you as you plan your biomanufacturing strategy and operations.